These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
90 related articles for article (PubMed ID: 3502169)
1. Augmentation of antileukemia lytic activity by OKT3 monoclonal antibody: synergism of OKT3 and interleukin-2. Lotzová E; Savary CA; Herberman RB; McCredie KB; Keating MJ; Freireich EJ Nat Immun Cell Growth Regul; 1987; 6(5):219-23. PubMed ID: 3502169 [TBL] [Abstract][Full Text] [Related]
2. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation. Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943 [TBL] [Abstract][Full Text] [Related]
3. Antileukemia activity of a natural killer cell line against human leukemias. Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753 [TBL] [Abstract][Full Text] [Related]
4. Induction of NK cell activity against fresh human leukemia in culture with interleukin 2. Lotzová E; Savary CA; Herberman RB J Immunol; 1987 Apr; 138(8):2718-27. PubMed ID: 3494084 [TBL] [Abstract][Full Text] [Related]
5. Preclinical studies for adoptive immunotherapy in bone marrow transplantation. Generation of anti-CD3 activated cytotoxic T cells from normal donors and autologous bone marrow transplant candidates. Ueda M; Joshi ID; Dan M; Uberti JP; Chou TH; Sensenbrenner LL; Lum LG Transplantation; 1993 Aug; 56(2):351-6. PubMed ID: 8356589 [TBL] [Abstract][Full Text] [Related]
6. Immunologic and clinical aspects of natural killer cells in human leukemia. Lotzová E; Savary CA; Pollock RE; Fuchshuber P Nat Immun Cell Growth Regul; 1990; 9(3):173-81. PubMed ID: 2370877 [TBL] [Abstract][Full Text] [Related]
7. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction. Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399 [TBL] [Abstract][Full Text] [Related]
8. The use of VEP13 monoclonal antibody for definition of natural killer cells: spontaneous killer cells directed against fresh human leukaemia cells carry the VEP13 antigen. Ziegler-Heitbrock HW; Fütterer A; Rumpold H; Kraft D; Munker R; Riethmüller G Clin Exp Immunol; 1984 Nov; 58(2):470-7. PubMed ID: 6333947 [TBL] [Abstract][Full Text] [Related]
9. Induction of cytotoxicity in human peripheral blood mononuclear cells by monoclonal antibody OKT3. Jung G; Martin DE; Müller-Eberhard HJ J Immunol; 1987 Jul; 139(2):639-44. PubMed ID: 3110277 [TBL] [Abstract][Full Text] [Related]
10. Induction of monocyte procoagulant activity with OKT3 antibody. Iitaka M; Iwatani Y; Row VV; Volpé R J Immunol; 1987 Sep; 139(5):1617-23. PubMed ID: 3114371 [TBL] [Abstract][Full Text] [Related]
11. Generation of NK cell activity from human bone marrow. Lotzová E; Savary CA J Immunol; 1987 Jul; 139(1):279-84. PubMed ID: 3495600 [TBL] [Abstract][Full Text] [Related]
12. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts. Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628 [TBL] [Abstract][Full Text] [Related]
13. Expansion of natural killer cells with lytic activity against autologous blasts from adult and pediatric acute lymphoid leukemia patients in complete hematologic remission. Torelli GF; Guarini A; Maggio R; Alfieri C; Vitale A; Foà R Haematologica; 2005 Jun; 90(6):785-92. PubMed ID: 15951291 [TBL] [Abstract][Full Text] [Related]
14. Lymphokine-activated and natural killer cell activity in human intestinal mucosa. Hogan PG; Hapel AJ; Doe WF J Immunol; 1985 Sep; 135(3):1731-8. PubMed ID: 3926882 [TBL] [Abstract][Full Text] [Related]
15. Cytotoxicity and clinical application of activated NK cells. Lotzová E Med Oncol Tumor Pharmacother; 1989; 6(1):93-8. PubMed ID: 2786121 [TBL] [Abstract][Full Text] [Related]
16. Progression of natural immunity during one-year treatment of residual disease in neuroblastoma patients with high doses of interleukin-2 after autologous bone marrow transplantation. Martí F; Pardo N; Peiró M; Bertran E; Amill B; García J; Cubells J; Rueda F Exp Hematol; 1995 Dec; 23(14):1445-52. PubMed ID: 8542930 [TBL] [Abstract][Full Text] [Related]
17. Combinational IL-2/IL-15 induction does not further enhance IL-15-induced lymphokine-activated killer cell cytotoxicity against human leukemia/lymphoma cells. Ozdemir O; Savaşan S Clin Immunol; 2005 Jun; 115(3):240-9. PubMed ID: 15893691 [TBL] [Abstract][Full Text] [Related]
18. Mode of in vitro augmentation of natural killer cell activity by recombinant human interleukin 2: a comparative study of Leu-11+ and Leu-11- cell populations in cord blood and adult peripheral blood. Seki H; Ueno Y; Taga K; Matsuda A; Miyawaki T; Taniguchi N J Immunol; 1985 Oct; 135(4):2351-6. PubMed ID: 3928745 [TBL] [Abstract][Full Text] [Related]
19. Cytotoxicity of interleukin 2-activated lymphocytes for leukemia and lymphoma cells. Oshimi K; Oshimi Y; Akutsu M; Takei Y; Saito H; Okada M; Mizoguchi H Blood; 1986 Oct; 68(4):938-48. PubMed ID: 3489494 [TBL] [Abstract][Full Text] [Related]
20. Tumor-directed cytotoxicity in multiple myeloma--the basis for an experimental treatment approach with interleukin 2. Peest D; Leo R; Deicher H Stem Cells; 1995 Aug; 13 Suppl 2():72-6. PubMed ID: 8520515 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]